Daiichi Sankyo's Savaysa tabs now available in pharmacies

TOKYO, Japan and PARSIPPANY, N.J. — Daiichi Sankyo on Monday announced that its Savaysa (edoxaban) tablets are now available in pharmacies across the United States. 

 

The drug was granted approval from the Food and Drug Administration on Jan. 8 and is used to reduce the risk of stroke and systemic embolism in patients who have a non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism, the company said.

 

“The availability of Savaysa provides appropriate patients and their physicians with a new anticoagulant that has been shown to reduce the risk of stroke and SE with significantly less major bleeding compared to warfarin in patients with NVAF and that treats venous thromboembolism with significantly less clinically relevant bleeding compared to warfarin,” said Howard Rutman, M.D., VP medical affairs at Daiichi Sankyo.

 

The launch of Savaysa brings the company's cardiovascular-metabolic product portfolio to seven FDA-approved treatments, according to Ken Keller, U.S. commerical at Daiichi Sankyo.

 

The company also announced the Savaysa Savings Plus program. Eligble patients who are prescibed the drug can enroll in the copay savings program and pay $4 a month through the Savaysa savings card. Vouchers are also available to give patients and doctors a way to try the drug at no cost if it is a right fit for the patient. Additionally, Savaysa's patient assistance program offers assistance to qualified patients, allowing them to receive free product if they are prescribed the drug, are uninsured and are not able to identify other payment sources.